supported by grants from the National Natural Science Foundation of China(Nos.81970344,82270411,82171464,82003321,and 82100713);the Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support(No.ZYLX202103);the Beijing Hospitals Authority’s Ascent Plan(No.DFL20220203);the China Postdoctoral Science Foundation(No.2021T140791).
Background:Renal ischemia–reperfusion(R-I/R)injury is the most prevalent cause of acute kidney injury,with high mortality and poor prognosis.However,the underlying pathological mechanisms are not yet fully understood...
Kidney disease remains a condition with an increasing incidence,high morbidity and mortality associated with cardiovascular events.The incidence of end-stage renal disease is expected to increase.Despite of the techni...
Solid organ transplantation offers life-saving treatment for patients with endorgan dysfunction.Patient survival and quality of life have improved over the past few decades as a result of pharmacological development,e...
the National Natural Science Foundation of China(Grant No.31271814;No.21702040);the Fundamental Research Funds for the Central Universities(Grant No.JZ2017HGPB0169;No.2014HFCH0011).
The renoprotective effects of Chinese chive water and ethanol extracts(CCWE and CCEE)on adenineinduced chronic renal failure(CRF)mice were evaluated in this study.Results showed that the renal pathological damages and...
grants from the Key Research and Development Program of Jiangsu Province (No.BE2016747); National Natural Science Foundation of China (No.81500548and No.81500556).
Background: Treatment with the dipeptidyl peptidase-4 inhibitors (DPP4i) and angiotensin receptor blockers (ARBs) in patients with type 2 diabetic nephropathy (DN) has not been well characterized. This study aimed to ...
Chronic kidney disease (CKD) is a significant public health problem as risk factors such as advanced age, obesity, hypertension and diabetes rise in the global po-pulation. Currently there are no effective pharmacol...
Background:Renin-angiotensin system inhibitor and calcium channel blocker (CCB) are widely used in controlling blood pressure (BP) in patients with chronic kidney disease (CKD).We carried out a meta-analysis to...
Chronic kidney disease (CKD) is a progressive disease and affects approximately 10% of the population. The major late pathologic feature of CKD is interstitial fibrosis in the kidney characterized by extracellular mat...
Aim: The possibility that angiotensin-converting enzyme inhibitors can protect hypertensive kidneys independently of any blood pressure (BP) decrease remains a matter of controversy. The present study investigates ...